spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  eosinophils 

 HSMN NewsFeed - 2 Feb 2023
Tezspire(R) Approved for Self-Administration in the U.S. with a New Pre-Filled Pen
Biopharmaceuticals Drug Delivery FDA
 HSMN NewsFeed - 20 Oct 2021
FDA Expands Approval of Dupixent(R) (dupilumab) to Include Children Aged 6 to 11 Years with Moderate-to-severe Asthma
Biopharmaceuticals FDA
 HSMN NewsFeed - 22 Dec 2020
Update On SOURCE Phase 3 Trial For Tezepelumab In Patients With Severe, Oral Corticosteroid-Dependent Asthma
Biopharmaceuticals
 HSMN NewsFeed - 10 Nov 2020
Tezepelumab NAVIGATOR Phase 3 Trial Met Primary Endpoint Of A Statistically Significant And Clinically Meaningful Reduction In Exacerbations In A Broad Population Of Patients With Severe Asthma
Biopharmaceuticals
 HSMN NewsFeed - 6 Aug 2019
Dupixent(R) (dupilumab) Approved by European Commission for Adolescents with Moderate-to-Severe Atopic Dermatitis
Biopharmaceuticals Dermatology Regulatory
 HSMN NewsFeed - 7 May 2019
Dupixent(R) (dupilumab) Approved for Severe Asthma by European Commission
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 1 Mar 2019
CHMP Recommends Approval of Dupixent(R) (dupilumab) for Asthma Indication
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 22 Oct 2018
FDA Approves Asthma Indication for Dupixent(R) (dupilumab)
Biopharmaceuticals FDA
 HSMN NewsFeed - 12 Dec 2017
FDA approves first drug for Eosinophilic Granulomatosis with Polyangiitis, a rare disease formerly known as the Churg-Strauss Syndrome
Biopharmaceuticals FDA
 HSMN NewsFeed - 29 Feb 2016
Genentech Provides Update On Two Identical Phase III Studies Of Lebrikizumab In People With Severe Asthma
Biopharmaceuticals
 HSMN NewsFeed - 19 Jan 2016
Allakos Successfully Completes Dosing in Phase 1 Clinical Trial of AK001 and Announces Expansion of its Executive Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Sep 2014
Successful Completion of Phase III Program for Teva’s Reslizumab Two More Phase Iii Studies Support the Benefits of Reslizumab Treatment in Asthma Patients with Eosinophilia
Biopharmaceuticals
 HSMN NewsFeed - 11 Oct 2013
FDA Files Genentech’s Supplemental Biologics License Application of Xolair(R) (omalizumab) for Chronic Idiopathic Urticaria (CIU)
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 1 Feb 2012
FDA approves Novartis drug Gleevec(R) label recommending extending treatment to three years for certain GIST patients after surgery
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 17 Oct 2011
Panmira Announces Appointment of New CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Jun 2009
Dermatologic and Ophthalmic Drugs Advisory Committee Unanimously Recommends Bepreve(TM) for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 15 Jan 2009
ISTA Pharmaceuticals' New Drug Application for Bepreve(TM) Accepted for Review by U.S. Food and Drug Administration
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 13 Jan 2009
Cephalon Signs Option Agreement to Acquire Ception Therapeutics
Biopharmaceuticals
 HSMN NewsFeed - 8 Jan 2009
TOPIGEN Pharmaceuticals Reports Phase 2 Results of TPI ASM8 in Asthma Patients
Biopharmaceuticals
 HSMN NewsFeed - 28 Nov 2007
Tasigna(R) gains European approval for patients with a life-threatening form of leukemia who are resistant or intolerant to existing therapies
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 29 Oct 2007
Tasigna(R) receives US approval providing new hope to chronic myeloid leukemia patients with resistance or intolerance to existing therapies
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 26 Sep 2007
ISTA Pharmaceuticals Expands Its Pipeline in Allergy Treatments
Biopharmaceuticals Licensing
 HSMN NewsFeed - 8 May 2007
ISTA Pharmaceuticals Announces Statistically Significant Preliminary Results From its U.S. Phase II/III Clinical Study Of Bepotastine
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 8 Jan 2007
Cambridge Antibody Technology Licenses Monoclonal Antibody (CAT-213) for Treatment of Allergy Disorders to iCo Therapeutics
Biopharmaceuticals Licensing
 HSMN NewsFeed - 21 Dec 2006
ISTA Pharmaceuticals Submits Investigational New Drug Application for Eye Drop Formulation of Bepotastine for the Treatment of Allergic Conjunctivitis
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 15 Nov 2006
Critical Therapeutics Announces Efficacy Data for Controlled-Release Formulation of Zileuton Presented at ACAAI 2006 Annual Meeting
Biopharmaceuticals
 HSMN NewsFeed - 19 Oct 2006
Gleevec(R) Approved in the US for Five Rare Life-Threatening Disorders With Limited Treatment Options
Biopharmaceuticals Oncology FDA
Return to NewsFeed  

 Additional items found! 4

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 4 additional stories matching:
eosinophils
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!